Evidence map›Paper›PMID 38890714›Full record

ArticleHuman genomics2024

Germline mutations of breast cancer susceptibility genes through expanded genetic analysis in unselected Colombian patients.

Diana Carolina Sierra-Díaz, Adrien Morel, Dora Janeth Fonseca-Mendoza, Nora Contreras Bravo, Nicolas Molano-Gonzalez, Mariana Borras, Isabel Munevar, Mauricio Lema, Henry Idrobo, Daniela Trujillo and 13 more

Abstract read
In one paragraph

Article in Human genomics, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

23 authors.

Diana Carolina Sierra-DíazSchool of Medicine and Health Sciences, Center for Research in Genetics and Genomics (CIGGUR), Institute of Translational Medicine (IMT), Universidad Del Rosario, Bogotá, Colombia.
Adrien MorelSchool of Medicine and Health Sciences, Center for Research in Genetics and Genomics (CIGGUR), Institute of Translational Medicine (IMT), Universidad Del Rosario, Bogotá, Colombia.
Dora Janeth Fonseca-MendozaSchool of Medicine and Health Sciences, Center for Research in Genetics and Genomics (CIGGUR), Institute of Translational Medicine (IMT), Universidad Del Rosario, Bogotá, Colombia.
Nora Contreras BravoSchool of Medicine and Health Sciences, Center for Research in Genetics and Genomics (CIGGUR), Institute of Translational Medicine (IMT), Universidad Del Rosario, Bogotá, Colombia.
Nicolas Molano-GonzalezClinical Research Group, School of Medicine and Health Science, Universidad del Rosario, Bogotá, Colombia.
Mariana BorrasFundación Cardioinfantil, Instituto de Cardiología, Bogotá, Colombia.
Isabel MunevarFundación Cardioinfantil, Instituto de Cardiología, Bogotá, Colombia.
Mauricio LemaClínica de Oncología Astorga, Medellín, Colombia.
Henry IdroboCentro Médico Julián Coronel, Cali, Colombia.
Daniela TrujilloCentro Médico Julián Coronel, Cali, Colombia.
Norma SerranoHospital Internacional de Colombia HIC, Piedecuesta, Colombia.
Ana Isabel OrduzHospital Internacional de Colombia HIC, Piedecuesta, Colombia.
Diego LoperaOncólogos del Occidente S.A.S, Manizales, Colombia.
Jaime GonzálezOncólogos del Occidente S.A.S, Manizales, Colombia.
Gustavo RojasOncólogos del Occidente S.A.S, Manizales, Colombia.
Paula Londono-De Los RíosOncólogos del Occidente S.A.S, Manizales, Colombia.
Ray MannehSOHEC, Sociedad de Oncología y Hematología del Cesar, Valledupar, Colombia.
Rodrigo CabreraSchool of Medicine and Health Sciences, Center for Research in Genetics and Genomics (CIGGUR), Institute of Translational Medicine (IMT), Universidad Del Rosario, Bogotá, Colombia.
Wilson RubianoHospital Universitario Mayor Méderi, Bogotá, Colombia.
Jairo de la PeñaHospital Universitario Mayor Méderi, Bogotá, Colombia.
María Catalina QuinteroIntegrative IPS, Bogotá, Colombia.
William MantillaFundación Cardioinfantil, Instituto de Cardiología, Bogotá, Colombia.
Carlos M RestrepoSchool of Medicine and Health Sciences, Center for Research in Genetics and Genomics (CIGGUR), Institute of Translational Medicine (IMT), Universidad Del Rosario, Bogotá, Colombia. carlos.restrepo@urosario.edu.co.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundIn Colombia and worldwide, breast cancer (BC) is the most frequently diagnosed neoplasia and the leading cause of death from cancer among women. Studies predominantly involve hereditary and familial cases, demonstrating a gap in the literature regarding the identification of germline mutations in unselected patients from Latin-America. Identification of pathogenic/likely pathogenic (P/LP) variants is important for shaping national genetic analysis policies, genetic counseling, and early detection strategies. The present study included 400 women with unselected breast cancer (BC), in whom we analyzed ten genes, using Whole Exome Sequencing (WES), know to confer risk for BC, with the aim of determining the genomic profile of previously unreported P/LP variants in the affected population. Additionally, Multiplex Ligation-dependent Probe Amplification (MLPA) was performed to identify Large Genomic Rearrangements (LGRs) in the BRCA1/2 genes. To ascertain the functional impact of a recurrent intronic variant (ATM c.5496 + 2_5496 + 5delTAAG), a minigene assay was conducted.

resultsWe ascertained the frequency of P/LP germline variants in BRCA2 (2.5%), ATM (1.25%), BRCA1 (0.75%), PALB2 (0.50%), CHEK2 (0.50%), BARD1 (0.25%), and RAD51D (0.25%) genes in the population of study. P/LP variants account for 6% of the total population analyzed. No LGRs were detected in our study. We identified 1.75% of recurrent variants in BRCA2 and ATM genes. One of them corresponds to the ATM c.5496 + 2_5496 + 5delTAAG. Functional validation of this variant demonstrated a splicing alteration probably modifying the Pincer domain and subsequent protein structure.

conclusionThis study described for the first time the genomic profile of ten risk genes in Colombian women with unselected BC. Our findings underscore the significance of population-based research, advocating the consideration of molecular testing in all women with cancer.

Indexed as

BRCA2 ProteinBreast NeoplasmsGenetic Predisposition to DiseaseGerm-Line MutationAdultAgedAtaxia Telangiectasia Mutated ProteinsBRCA1 ProteinColombiaExome SequencingFemaleGenetic TestingHumansMiddle AgedAtaxia Telangiectasia Mutated ProteinsBRCA1 ProteinBRCA1 protein, humanBRCA2 ProteinBRCA2 protein, humanMinigene assayPathogenic germline variantsUnselected breast cancerWhole exome sequencing

Identifiers

PMID38890714
PMCPMC11184794

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.